Astrazeneca plc - ADR

AZN

$64.79

-2.3% last 12 months

PRIMECAP Management Holding value: $2.84 Billion Ken Fisher Holding value: $594 Million Jim Simons Holding value: $113 Million Ken Griffin Holding value: $50.1 Million Ron Baron Holding value: $15.5 Million Ray Dalio Holding value: $7.37 Million Jefferies Group Holding value: $776 Thousand Paul Tudor Jones II Holding value: $419 Thousand Charles Brandes Holding value: $0 John W. Rogers Jr. Holding value: $0 Andreas Halvorsen Holding value: $0 Baillie Gifford Holding value: $0 Steven Cohen Holding value: $0 Jeremy Grantham Holding value: $0 Julian Robertson Holding value: $0 Joel Greenblatt Holding value: $0 Mario Gabelli Holding value: $0 Chris Davis Holding value: $0 Stanley Druckenmiller Holding value: $0 George Soros Holding value: $0 Prem Watsa Holding value: $0

Market Cap

$200 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$60.82 - $75.56

The lowest and highest price in the last 52 weeks.

Price-Earnings Ratio

33.97x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$1.44 (2.23%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to
Market
Industry
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $200 Billion
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt. $224 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. $1.44 (2.23%)
1 Year Return Profit or loss of share price change plus dividend yield. -0.1%
52-Week High Highest share price in the last 52 weeks. $75.56
52-Week Low Lowest share price in the last 52 weeks. $60.82
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return. 0.0
Outstanding Shares The number of shares the company has issued and are held by stockholders. 3.1 Billion
Avg 30 Day Volume The number of shares traded in the last 30 days. 5.75 Million

Valuation

Compare to
Market
Industry
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 33.97
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. -208.13
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value. $1.89
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 4.63
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 5.89
Enterprise Value to Revenue Enterprise value divided by revenue 4.97
Enterprise Value to EBIT Enterprise Value divided by EBIT 29.49
Total Debt to Enterprise Value Total debt divided by enterprise value 0.13
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. 0.77

Profitability

Compare to
Market
Industry
Revenue Revenue is the sum of all cash flow into the company. $45 Billion
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services. $36.1 Billion
EBIT Earnings before tax and interest payments. $7.59 Billion
Net Income Net Income is the profit after all expenses have been deducted from the total revenue. $5.89 Billion
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. 13.10%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. -16.3%
Return on Equity Equity divided by market cap. 15.85%
Return on Assets Indicates a company's profitability in relation to its total assets. 6.13%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. 11.24%

Insider trades

No purchases

No sells

No purchases

No sells

No purchases

No sells

No purchases

No sells

Q1 2023 Q2 2023 Q3 2023 Q4 2023

About Astrazeneca plc - ADR

CEO: Pascal Soriot

Industry: Pharmaceuticals: Major

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Similar stocks

Pfizer Inc.
Pfizer Inc.
Merck & Co Inc
Merck & Co Inc
GSK Plc - ADR
GSK Plc - ADR
Sanofi - ADR
Sanofi - ADR
Lilly(Eli) & Co
Lilly(Eli) & Co
Johnson & Johnson
Johnson & Johnson
Abbott Laboratories
Abbott Laboratories
Biogen Inc
Biogen Inc
Novartis AG - ADR
Novartis AG - ADR

News

AstraZeneca halts Phase III trials for kidney disease treatment

AstraZeneca halts Phase III trials for kidney disease treatment

https://www.investing.com/news/stock-market-news/astrazeneca-halts-phase-iii-trials-for-kidney-disease-treatment-93CH-3247727

Investing.com Investing.com, 3 days ago
BUSINESS LIVE: Abu Dhabi group buys London developer; Dominos Pizza firm faces takeover; AZN ditches drug trial

BUSINESS LIVE: Abu Dhabi group buys London developer; Dominos Pizza firm faces takeover; AZN ditches drug trial

Among the companies with reports and trading updates today are AstraZeneca, London Square, DP Eurasia and Rentokil.

This is Money This is Money, 3 days ago
AstraZeneca advances scientific leadership in hematology at ASH 2023

AstraZeneca advances scientific leadership in hematology at ASH 2023

AstraZeneca will present new clinical and real-world data in multiple hematological conditions at the 65th American Society of Hematology (ASH) Annual Meetin...

Wallstreet:Online Wallstreet:Online, 5 days ago
R&D plans by drug giant AstraZeneca shot in arm for Hong Kong’s biomedical hub bid

R&D plans by drug giant AstraZeneca shot in arm for Hong Kong’s biomedical hub bid

AstraZeneca decision follows Hong Kong labs move by UN vaccine body and Cambridge University.

South China Morning Post South China Morning Post, 6 days ago
Never miss a trade
To improve your user experience we use cookies.